Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon‐β
- 8 December 2008
- journal article
- research article
- Published by Wiley in European Journal of Neurology
- Vol. 16 (1) , 43-47
Abstract
Background and purpose: Neutralizing antibodies (NAbs) appearing during treatment with Interferon‐beta (IFN‐β) reduce or abolish bioactivity and therapeutic efficacy. Initial combination therapy with methylprednisolone (MP) may reduce the frequency of NAb positive patients. We hypothesized that MP treatment might also reduce NAb levels and re‐establish IFN‐β bioactivity in patients already NAb+, who discontinue IFN‐β therapy. Methods: In a 6‐month open‐label trial, we compared monthly high‐dose pulsed MP treatment in 38 Nab positive patients with 35 NAb+, MP‐untreated control patients discontinuing any therapy or switching to glatiramer acetate. All patients were NAb+ with an absent in vivo response to IFN‐β. NAbs were measured using a cytopathic effect assay and expressed as neutralizing capacity (NC) in percentage of added IFN‐β. Bioactivity was expressed as in vivo Myxovirus Resistance Protein A (MxA) mRNA induction in whole blood using real time PCR. Results: At the end of study, median NAb NC was 92% in both groups. Eight patients (21%) in the MP group and four patients (11%) in the control group had regained an in vivo MxA response to IFN‐β (P = 0.35). Conclusions: Monthly pulsed MP treatment in NAb positive patients has no beneficial effect on NAb status or IFN‐β bioactivity.Keywords
This publication has 22 references indexed in Scilit:
- In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependentJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Using measurements of neutralizing antibodies: the challenge of IFN‐β therapyEuropean Journal of Neurology, 2007
- Dynamics of interferon-β modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-β neutralizing antibodiesJournal of Neuroimmunology, 2006
- Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosisEuropean Journal of Neurology, 2005
- Neutralizing antibodies and efficacy of interferon β-1aNeurology, 2005
- Appearance and disappearance of neutralizing antibodies during interferon-beta therapyNeurology, 2005
- Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1bNeurology, 2003
- Evaluation of bioavailability of three types of IFNβ in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantificationJournal of Immunological Methods, 2001
- PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MSNeurology, 2001
- Interferon β neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparationsImmunopharmacology, 2000